Nils Age Brünner

Q: What Schools Are Affiliated With Nils Age Brünner

Nils Age Brünner is affiliated with the following schools: University of Southern Denmark, Royal Veterinary and Agricultural University, Lund University, University of Copenhagen

Nils Age Brünner's AcademicInfluence.com Rankings

Nils Age Brünner

Biology

#13456

World Rank

#17001

Historical Rank

Bioinformatics

#170

World Rank

#172

Historical Rank

Computational Biology

#316

World Rank

#317

Historical Rank

Microbiology

#833

World Rank

#915

Historical Rank

biology Degrees

Download Badge

Biology

Nils Age Brünner's Degrees

PhD Bioinformatics University of Copenhagen
Masters Biology University of Copenhagen
Bachelors Biology University of Copenhagen

Similar Degrees You Can Earn

Why Is Nils Age Brünner Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Nils Age Brünner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer (2015) (673)
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. (2002) (619)
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. (2008) (603)
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines (1992) (548)
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. (1993) (431)
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. (2000) (420)
The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies (2001) (337)
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. (1994) (322)
The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion (1995) (307)
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. (1999) (296)
High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients (2010) (276)
Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue (1999) (244)
Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. (1993) (201)
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. (1995) (190)
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. (1994) (188)
Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. (2000) (186)
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. (1998) (185)
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. (2000) (167)
ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. (1997) (161)
Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer (1999) (155)
Time‐dependent, spontaneous release of white cell‐ and platelet‐derived bioactive substances from stored human blood (1996) (154)
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. (2002) (144)
Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. (1998) (142)
Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. (2002) (138)
Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis (1999) (136)
Tumor Tissue Levels of Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Marker in Primary Breast Cancer (2004) (134)
High Serum YKL-40 Levels in Patients with Primary Breast Cancer is Related to Short Recurrence Free Survival (2003) (129)
Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids (2011) (128)
Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer (2000) (122)
External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. (1998) (121)
Tissue inhibitor of metalloproteinases-1 in breast cancer. (2005) (119)
Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials (1993) (112)
Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. (2002) (111)
Banking of Biological Fluids for Studies of Disease-associated Protein Biomarkers* (2008) (108)
Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). (2002) (107)
Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. (2008) (106)
Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. (1989) (104)
A cleaved form of the receptor for urokinase‐type plasminogen activator in invasive transplanted human and murine tumors (1994) (97)
Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. (2000) (97)
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness (1996) (95)
Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. (1999) (94)
Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 (2011) (90)
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients (2003) (87)
Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer (1998) (86)
High expression of microRNA‐625‐3p is associated with poor response to first‐line oxaliplatin based treatment of metastatic colorectal cancer (2013) (84)
TIMP-1 Is Significantly Associated with Objective Response and Survival in Metastatic Colorectal Cancer Patients Receiving Combination of Irinotecan, 5-Fluorouracil, and Folinic Acid (2007) (84)
Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance (2015) (84)
S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. (2001) (83)
Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. (2008) (83)
TIMP-1 as a tumor marker in breast cancer – An update (2008) (83)
Tumor Tissue Concentrations of the Proteinase Inhibitors Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor Type 1 (PAI-1) Are Complementary in Determining Prognosis in Primary Breast Cancer * (2003) (82)
Expression of urokinase plasminogen activator, its receptor and type‐1 inhibitor in malignant and benign prostate tissue (2005) (81)
Primary Tumor Levels of Tissue Inhibitor of Metalloproteinases-1 Are Predictive of Resistance to Chemotherapy in Patients with Metastatic Breast Cancer (2006) (80)
Soluble Urokinase Plasminogen Activator Receptor Measurements: Influence of Sample Handling (2001) (79)
Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis (2002) (79)
Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals (2011) (77)
Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. (1996) (77)
Soluble vascular endothelial growth factor in various blood transfusion components (1999) (77)
Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. (2002) (76)
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer (2004) (76)
Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. (1998) (76)
TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis (2006) (75)
Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines (1997) (74)
Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival (2009) (74)
lncRNA profile study reveals the mRNAs and lncRNAs associated with docetaxel resistance in breast cancer cells (2018) (73)
Tumor Markers (2003) (72)
Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells (1998) (71)
Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. (2001) (70)
Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. (1997) (70)
Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. (1995) (70)
lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. (1992) (69)
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice (2003) (69)
Anti‐proliferative and anti‐estrogenic effects of ICI 164,384 and ICI 182,780 in 4‐OH‐tamoxifen‐resistant human breast‐cancer cells (1994) (68)
Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study. (2004) (67)
Leucocyte-derived bioactive substances in fresh frozen plasma. (1997) (62)
Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines. (1998) (62)
The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study (2008) (61)
The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer (1999) (61)
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. (2005) (61)
Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment (2008) (57)
Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. (2003) (57)
Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 (2010) (57)
HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. (2010) (55)
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer (2013) (55)
Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study. (2010) (54)
Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion (1994) (54)
Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. (2006) (53)
Genetic instability of cell lines derived from a single human small cell carcinoma of the lung. (1985) (53)
1α,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cellsin vitro (1994) (53)
Rapid and Individual-specific Glycoprofiling of the Low Abundance N-Glycosylated Protein Tissue Inhibitor of Metalloproteinases-1*S (2007) (53)
Localization of tissue inhibitor of metalloproteinases 1 (TIMP‐1) in human colorectal adenoma and adenocarcinoma (2005) (52)
Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway. (2008) (52)
Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties (2013) (52)
Data fusion in metabolomic cancer diagnostics (2012) (52)
Urokinase-Type Plasminogen Activator System in Breast Cancer (2004) (51)
Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells--associations with histopathology and patients outcome. (2010) (50)
Comparative evaluation of urokinase‐type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells (2003) (49)
Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. (2006) (49)
Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue. (2007) (48)
Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). (1993) (47)
TIMP‐1 expression in human colorectal cancer is associated with TGF‐B1, LOXL2, INHBA1, TNF‐AIP6 and TIMP‐2 transcript profiles (2008) (47)
Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. (2001) (47)
High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression (2009) (46)
High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI‐2) is an independent marker for shorter progression‐free survival in patients with early stage endometrial cancer (2002) (46)
BMP-2 induces EMT and breast cancer stemness through Rb and CD44 (2017) (46)
Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance (2017) (45)
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours (2001) (45)
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. (1997) (44)
Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research* (2003) (44)
Serum YKL-40 in Risk Assessment for Colorectal Cancer: A Prospective Study of 4,496 Subjects at Risk of Colorectal Cancer (2015) (44)
Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review (2013) (43)
The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. (2000) (42)
Plasma and Serum Levels of Tissue Inhibitor of Metalloproteinases-1 Are Associated with Prognosis in Node-negative Breast Cancer (2008) (42)
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 (2010) (42)
Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies (2011) (42)
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies (1995) (40)
Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals (2013) (40)
Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. (2010) (40)
Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development (2013) (40)
Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies (1999) (40)
In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. (1998) (39)
Loss of ELISA specificity due to biotinylation of monoclonal antibodies. (2000) (39)
Cathepsin B/Cystatin C Complex Levels in Sera from Patients with Lung and Colorectal Cancer (2001) (38)
Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations. (2007) (38)
Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): A novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection (2008) (38)
Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review (2017) (38)
Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways (2015) (38)
Complexes between urokinase‐type plasminogen activator and its receptor in blood as determined by enzyme‐linked immunosorbent assay (1998) (37)
European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers. (2007) (37)
Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. (2007) (36)
Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer (2008) (35)
Detection of colorectal neoplasia: Combination of eight blood‐based, cancer‐associated protein biomarkers (2017) (35)
Plasma TIMP-1 in patients with colorectal adenomas: a prospective study. (2004) (35)
Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay. (2003) (34)
Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study. (2009) (34)
Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. (2001) (34)
Serum steroid levels in intact and endocrine ablated BALB/c nude mice and their intact littermates. (1986) (34)
Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. (2001) (33)
Characterization of Anti-TIMP-1 Monoclonal Antibodies for Immunohistochemical Localization in Formalin-fixed, Paraffin-embedded Tissue (2006) (33)
Migratory, invasive and metastatic capacity of NCAM transfected rat glioma cells (1993) (33)
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines (2015) (33)
TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells. (2013) (33)
Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence (2004) (32)
Hormone resistance, invasiveness, and metastatic potential in breast cancer (1993) (32)
Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay. (2002) (32)
XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro (2004) (32)
Assays for the study of human cancer cell invasion and metastasis (1992) (32)
The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis. (2006) (31)
Investigating the biomarker potential of glycoproteins using comparative glycoprofiling - application to tissue inhibitor of metalloproteinases-1. (2008) (31)
Comparison of characteristics of human small cell carcinoma of the lung in patients, in vitro and transplanted into nude mice. (2009) (31)
1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. (1994) (31)
Disaggregation of human solid tumours by combined mechanical and enzymatic methods. (1985) (31)
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. (2005) (30)
Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer (2016) (30)
Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer. (2001) (30)
Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. (1994) (30)
Indication of a role of plasminogen activator inhibitor type 1 in protecting murine fibrosarcoma cells against apoptosis (2005) (30)
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients (1997) (29)
Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas (2018) (29)
Leucocyte and platelet‐derived bioactive substances in stored blood: effect of prestorage leucocyte filtration (1997) (29)
Effect of tamoxifen on the receptor-positive T61 and the receptor-negative T60 human breast carcinomas grown in nude mice. (1985) (29)
Establishment and Characterization of 7 New Monoclonal Antibodies to Tissue Inhibitor of Metalloproteinases-1 (2005) (28)
Molecular Analysis of Two Mammary Carcinoma Cell Lines at the Transcriptional Level as a Model System for Progression of Breast Cancer (1998) (28)
Effect of 17 beta-oestradiol on growth curves and flow cytometric DNA distribution of two human breast carcinomas grown in nude mice. (1983) (28)
Positron emission tomography/computed tomography for optimized colon cancer staging and follow up (2013) (28)
Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer (2012) (28)
A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer (2008) (28)
Quantification of Tissue Inhibitor of Metalloproteinases 2 in Plasma from Healthy Donors and Cancer Patients (2005) (27)
TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity (2012) (27)
Measurement of the Uncomplexed Fraction of Tissue Inhibitor of Metalloproteinases-1 in the Prognostic Evaluation of Primary Breast Cancer Patients* (2005) (27)
Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer. (2004) (27)
A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification (2016) (27)
Immunoreactive opioid peptides in human breast cancer. (1989) (27)
High Plasma TIMP-1 and Serum CEA Levels during Combination Chemotherapy for Metastatic Colorectal Cancer Are Significantly Associated with Poor Outcome (2010) (26)
Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study (2013) (26)
Screening for colorectal cancer: possible improvements by risk assessment evaluation? (2011) (26)
The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells (2016) (25)
High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study. (2007) (25)
Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals. (2015) (25)
Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane. (1994) (24)
Impact of elective resection on plasma TIMP‐1 levels in patients with colon cancer (2006) (24)
TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes (2014) (24)
Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort (2013) (24)
Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator (2009) (24)
Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis. (2005) (23)
Coexisting genomic aberrations associated with lymph node metastasis in breast cancer (2018) (23)
The nude mouse as an in vivo model for human breast cancer invasion and metastasis. (1993) (23)
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer. (2011) (23)
Topoisomerase‐1 and ‐2A gene copy numbers are elevated in mismatch repair‐proficient colorectal cancers (2015) (23)
p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis. (1996) (23)
Characterization of the T61 human breast carcinoma established in nude mice. (1985) (23)
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations (2016) (21)
The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells (2015) (21)
Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer (2010) (21)
Cross-resistance and molecular mechanisms in antiestrogen resistance (1995) (21)
Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis (2013) (21)
Cathepsin B/Cystatin C Complex Levels in Sera from Patients with Lung and Colorectal Cancer (2001) (20)
Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study (2009) (19)
A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1 (2010) (19)
TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression (2013) (18)
Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients. (1999) (18)
Endocrine sensitivity of the receptor‐positive T61 human breast carcinoma serially grown in nude mice (1985) (18)
Elevated plasma levels of TIMP‐1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders (2003) (18)
Measuring ERCC1 protein expression in cancer specimens: Validation of a novel antibody (2014) (18)
Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer (2013) (18)
Dose-dependent effect of 17 beta-estradiol determined by growth curves and flow cytometric DNA analysis of a human breast carcinoma (T61) grown in nude mice. (1985) (18)
The use of the CELLection kit in the isolation of carcinoma cells from mononuclear cell suspensions. (2000) (17)
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. (1997) (16)
Emerging biomarkers in breast cancer care. (2010) (16)
ELISA for complexes between urokinase‐type plasminogen activator and its receptor in lung cancer tissue extracts (1997) (16)
Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer (2013) (16)
The plasminogen activation system and its role in lung cancer. A review. (1995) (16)
In vitro drug responses in primary and metastatic colorectal cancers (2011) (15)
Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells (1998) (15)
Plasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive fibromatosis (desmoid tumor) (2005) (15)
Drug Resistance in Colorectal Cancer Cell Lines is Partially Associated with Aneuploidy Status in Light of Profiling Gene Expression. (2016) (15)
PPARα and PPARγ are co‐expressed, functional and show positive interactions in the rat urinary bladder urothelium (2009) (15)
Cytokeratin-positive cells in preoperative peripheral blood and bone marrow aspirates of patients with colorectal cancer (2002) (15)
Chemosensitivity of human small cell carcinoma of the lung detected by flow cytometric DNA analysis of drug-induced cell cycle perturbations in vitro. (1986) (15)
Growth inhibition in response to estrogen withdrawal and tamoxifen therapy of human breast cancer xenografts evaluated by in vivo 31P magnetic resonance spectroscopy, creatine kinase activity, and apoptotic index. (1995) (15)
Identification of alternatively spliced TIMP‐1 mRNA in cancer cell lines and colon cancer tissue (2007) (15)
Bacterial antigen-induced release of white cell- and platelet-derived bioactive substances in vitro (2002) (14)
The T61 human breast cancer xenograft: An experimental model of estrogen therapy of breast cancer (2005) (14)
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial (2015) (14)
Changes in plasma TIMP-1 levels after resection for primary colorectal cancer. (2009) (14)
Preoperative Plasma Soluble Urokinase Plasminogen Activator Receptor as a Prognostic Marker in Rectal Cancer Patients. An Eortc-Receptor and Biomarker Group Collaboration (2005) (13)
Topoisomerase‐1 gene copy aberrations are frequent in patients with breast cancer (2015) (13)
Gender-dependent physiological implications of combined PAI-1 and TIMP-1 gene deficiency characterized in a mouse model. (2007) (13)
Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera (2002) (13)
TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients (2012) (13)
Evaluating TIMP‐1, Ki67, and HER2 as markers for non‐sentinel node metastases in breast cancer patients with micrometastases to the sentinel node (2011) (13)
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer (2017) (13)
Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer. (2010) (13)
Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer. (2014) (13)
TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas (2015) (12)
Discovery and Validation of Plasma-Protein Biomarker Panels for the Detection of Colorectal Cancer and Advanced Adenoma in a Danish Collection of Samples from Patients Referred for Diagnostic Colonoscopy. (2016) (12)
Oestrogen receptor assay. False positive analysis? (1984) (12)
The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer (2015) (12)
Steroid metabolism in the hormone dependent MCF-7 human breast carcinoma cell line and its two hormone resistant subpopulations MCF-7 LCC1 and MCF-7 LCC2 (1997) (11)
Leucocyte and platelet derived bioactive substances in stored standard platelet concentrates (1996) (11)
Chemoradiation-induced changes in serum CEA and plasma TIMP-1 in patients with locally advanced rectal cancer. (2010) (11)
TOP2A , TIMP-1 and responsiveness to adjuvant anthracycline containing chemotherapy in high risk breast cancer patients. (2009) (11)
Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study (2012) (11)
The nude mouse as anin vivo model for human breast cancer invasion and metastasis (2005) (11)
DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer (2015) (11)
Preoperative concentrations of suPAR and MBL proteins are associated with the development of pneumonia after elective surgery for colorectal cancer. (2006) (11)
Effect of NCAM‐transfection on growth and invasion of a human cancer cell line (1997) (11)
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol (2015) (10)
Lack of TIMP-1 tumor cell immunoreactivity predicts effect of adjuvant anthracycline based chemotherapy in patients (n=647) with primary breast cancer. (2009) (10)
Effect of melphalan on growth curves and cell cycle distribution of four human small cell carcinomas of the lung grown in nude mice. (1986) (10)
Immunoelectron microscopy of the receptor for urokinase plasminogen activator and cathepsin D in the human breast cancer cell line MDA‐MB‐231 (1994) (10)
IGF-I and IGF-II expression in human breast cancer xenografts: Relationship to hormone independence (2005) (9)
Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer (2013) (9)
Purification and characterization of bioactive his6-tagged recombinant human tissue inhibitor of metalloproteinases-1 (TIMP-1) protein expressed at high yields in mammalian cells. (2014) (9)
Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab (2015) (9)
PPARα and PPARγ Coactivation Rapidly Induces Egr-1 in the Nuclei of the Dorsal and Ventral Urinary Bladder and Kidney Pelvis Urothelium of Rats (2009) (9)
Increased serological cancer-associated biomarker levels at large bowel endoscopy and risk of subsequent primary cancer† (2016) (9)
A Comprehensive RNA Study to Identify circRNA and miRNA Biomarkers for Docetaxel Resistance in Breast Cancer (2021) (9)
The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP (2020) (9)
Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma‐soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism (2003) (9)
Endocrine therapy of human breast cancer grown in nude mice (1987) (8)
Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line. (2020) (8)
Abstract A116: Targeting the Wnt-5a signaling pathway as a novel anti-metastatic therapy (2015) (8)
Urokinase-type receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies (1994) (8)
Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat (2001) (8)
TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer (2015) (7)
Blood-based Biomarkers at Large Bowel Endoscopy and Prediction of Future Malignancies (2015) (7)
Phase I dose-escalating study to evaluate the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of Foxy-5 in patients with metastatic breast, colorectal, or prostate cancer. (2014) (7)
Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue (2016) (7)
Estradiol Enhances Osteolytic Lesions in Mice Inoculated with Human Estrogen Receptor-Negative MDA-231 Breast Cancer Cells in vivo (2003) (7)
The role of Serpine-1 and Tissue inhibitor of metalloproteinase type-1 in early host responses to Staphylococcus aureus intracutaneous infection of mice. (2013) (7)
Immunoassays of urokinase (uPA) and its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue. (2003) (7)
Serum Cathepsin H as a Potential Prognostic Marker in Patients with Colorectal Cancer (2004) (7)
Proximity probing assays for simultaneous visualization of protein complexes in situ (2013) (7)
Identifying sources and estimating glandular output of salivary TIMP‐1 (2008) (7)
Soluble urokinase plasminogen activator receptor in blood transfusion components (2004) (6)
Histologic changes following oestradiol treatment of a hormone-responsive human breast carcinoma grown in nude mice. (2009) (6)
Drug transporters in breast cancer: response to anthracyclines and taxanes (2015) (6)
Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer (2010) (6)
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group (2014) (6)
Salivary tissue inhibitor of metalloproteinases‐1 localization and glycosylation profile analysis (2011) (6)
The Urokinase Plasminogen Activation System in Breast Cancer (1999) (6)
An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort (2013) (6)
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer (2016) (6)
Tissue inhibitor of metalloproteinase‐1 levels in plasma from tumour arteries and veins of patients with rectal cancer (2007) (6)
Estimation by Flow Cytometric DNA Analysis of the Effect of Radiotherapy, Hormone Therapy and Chemotherapy on Human Tumors Grown in Nude Mice (1984) (6)
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. (2011) (6)
Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma (2014) (6)
Expression Patterns of Biomarkers in Primary Tumors and Corresponding Metastases in Breast Cancer (2016) (5)
An Explorative Analysis of ABCG2/TOP-1 mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 Trial (2020) (5)
Biomarkers for therapeutic efficacy (2007) (5)
Biological variations in plasma VEGF and VEGFR-1 may compromise their biomarker value in colorectal cancer (2010) (5)
Tumor invasion and metastasis (2001) (5)
Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with bladder cancer. (2006) (5)
Four phase 1 trials to evaluate the safety and pharmacokinetic profile of single and repeated dosing of SCO‐101 in adult male and female volunteers (2020) (5)
Application of Endocrine Therapy in the Nude Mouse Model1 (1987) (5)
Genetic Instability of Human Solid Tumors Grown in Nude Mice (1984) (5)
Growth kinetics of four human breast carcinomas grown in nude mice (1989) (5)
Tissue inhibitor of metalloproteinases-1 protects the human breast carcinoma cell line MCF-7 S1 against anthracycline-induced cell death by activation of the akt survival pathway. (2009) (5)
Clinical Infrastructures to Support Proteomic Studies of Tissue and Fluids in Breast Cancer* (2004) (5)
A new immunocapture assay for Escherichia coli beta-galactosidase for in vivo studies of lacZ-transduced tumor cells. (1998) (5)
Abstract A144: Sensitization of docetaxel-resistant breast cancer cells to docetaxel by the VRAC modulator SCO-101 (2018) (4)
Progesterone Receptor Isoform Analysis by Quantitative Real-Time Polymerase Chain Reaction in Formalin-Fixed, Paraffin-Embedded Canine Mammary Dysplasias and Tumors (2014) (4)
Investigation of tissue inhibitor of metalloproteinases 1 in plasma from colorectal cancer patients and blood donors by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. (2007) (4)
ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer (2020) (4)
In vivo/in vitro Selection of Hormone-Independent Cells from the Hormone-Dependent MCF-7 Human Breast Cancer Cell Line (1989) (4)
Tissue Inhibitor Of Matrix Metalloproteinase-1 Is Required for High-Fat Diet-Induced Glucose Intolerance and Hepatic Steatosis in Mice (2015) (4)
Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer (2007) (4)
Title Page / Contents / Preface / Opening Remarks / 5th Internalional Workshop on Immune-Deficient Animals in Biomedical Research (1987) (4)
A TIMP-1 splice variant transcript: possible role in regulation of TIMP-1 expression. (2008) (4)
Detection of endocrine responsiveness by flow cytometric DNA analysis in experimental human breast cancer. (1984) (4)
New use for old drugs: Epirubicin in colorectal cancer (2021) (4)
TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line (2013) (4)
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene (2019) (4)
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial? (2013) (4)
Serum YKL-40 in risk assessment for colorectal cancer: A prospective study of 4496 subjects at risk of colorectal cancer (2014) (4)
Abstract A143: Repurposing disulfiram as a potential novel treatment of drug-resistant metastatic colorectal cancer (2018) (4)
Plasma Escherichia Coli β-Galactosidase as a Marker of Tumor Burden and Response to Experimental Anti-Neoplastic Therapy in Nude Mice Xenografted with lacZ Transduced Human Tumor Cells (2000) (3)
Early detection of recurrence after curative resection for colorectal cancer – obstacles when using soluble biomarkers? (2013) (3)
MicroRNAs related to intrinsic resistance to oxaliplatin and the irinotecan metabolite SN-38 in 10 colorectal cancer cell lines. (2012) (3)
[Serological markers of colorectal cancer]. (2005) (3)
ABCG2 and TOP1 mRNA expression as predictive biomarkers for adjuvant FOLFIRI treatment in stage III colon cancer patients: Results from the PETAAC-3 prospective randomized clinical trial. (2017) (3)
Comparative Analysis of Evolutionarily Conserved Motifs of Epidermal Growth Factor Receptor 2 (HER2) Predicts Novel Potential Therapeutic Epitopes (2014) (3)
Serum YKL-40 in risk assessment for colorectal cancer. A population based, prospective study of 4,987 subjects at risk of colorectal cancer (2008) (3)
Characterization of the T60 Human Breast Carcinoma Grown in Nude Mice (1987) (3)
Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group (2012) (3)
Directions for further improvements of treatment of metastatic colorectal cancer (2012) (3)
Abstract P3-06-32: Topoisomerase 1 gene copy aberration is a frequent finding in clinical breast cancer samples (2012) (3)
Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines (2017) (3)
Invasion and metastasis factors in breast cancer (1993) (3)
Etirinotecan pegol: an option for late-stage breast cancer? (2013) (3)
Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients (2012) (3)
Abstract P5-07-08: Identification and characterization of a new TIMP-1 binding protein (2015) (2)
Limitations of tissue micro array in Duke's B colon cancer (2012) (2)
P1-06-03: Predictive Value of HER2, Topoisomerase-II (Topo-II) and Tissue Inhibitor of Metalloproteinases (TIMP-1) for Efficacy of Taxane-Based Chemotherapy in Intermediate Risk Breast Cancer – Results from the EC-Doc Trial. (2011) (2)
EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY (2013) (2)
Colorectal cancer cell lines made resistant to SN38‐and Oxaliplatin: Roles of altered ion transporter function in resistance? (2013) (2)
Prediction of responsiveness to adjuvant anthracyclines in high-risk breast cancer patients. (2016) (2)
Plasminogen activator inhibitor type 1 (PAI-1), in cancer: A potential new target for antiinvasive and antimetastatic therapy (1998) (2)
Tissue Inhibitor of Metalloproteinases-1 as a Biological Marker in Colorectal Cancer: Influence of Smoking on Plasma Levels? (2013) (2)
Dissemination in athymic nude mice of lacZ transfected small cell lung cancer cells identified by X‐gal staining (1995) (2)
Syddansk Universitet A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP 2 A gene amplification (2016) (2)
Screening of 129 FDA approved anti-cancer drugs in colorectal cancer cell lines resistant to oxaliplatin or irinotecan (SN38). (2017) (2)
Use of microRNA to identify stage IV breast cancer patients to be targeted with phospholipase A2 disrupted cisplatin carrying liposomes: An ongoing phase I trial. (2014) (2)
Investigation of Tissue Inhibitor of Metalloproteinases 1 in Plasma from Colorectal Cancer Patients and Blood Donors by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (2007) (2)
Fulvestrant response prediction from transcriptome data obtained from primary breast cancer biopsies. (2016) (2)
The serological markers TIMP-1, PAI-1, MASP-2 and CRP are independent predictors of colorectal cancer-specific death. (2006) (2)
Marker of erosive progression in RA (2000) (2)
Assessment of the Biological Variation of Plasma Tissue Inhibitor of Metalloproteinases-1 (2008) (2)
P84-T Rapid and Individual-Specific Glycoprofiling of the Low-Abundant Plasma Protein Tissue Inhibitor of Metalloproteinases-1 (2007) (1)
Novel Methods in the Study of the Breast Cancer Genome: Towards a Better Understanding of the Disease of Breast Cancer (2012) (1)
DEN-50R - establisment of a novel and unique cell line based drug screening platform for cancer treatment (2015) (1)
Positron emission tomography/computed tomography for optimized colon cancer staging and follow-up. (2014) (1)
TIMP-1 and responsiveness of estrogen receptor negative breast cancer to preoperative epirubicin and cyclophosphamide with or without gefitinib (2009) (1)
New Tumor Biomarkers (2008) (1)
Abstract P3-06-35: Topoisomerase 1 gene copy aberrations in 52 human breast cancer cell lines and association to gene expression (2012) (1)
Abstract 1214: TIMP-1 and the TIMP-1 interacting cell surface protein CD63 in cultured astrocytoma derived spheroids: expression and co-expression with stem cell markers (2010) (1)
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial? (2013) (1)
PLASMINOGEN ACTIVATOR SYSTEM IN BREAST CANCER TISSUE AND BLOOD : CLINICAL RELEVANCE AND METHODOLOGICAL CONSIDERATIONS (1998) (1)
116 Elisa determination of the complex between urokinase plasminogen activator and its type-1 inhibitor in tumor extracts (1997) (1)
Steroid Receptor Profile in Human Breast Cancer Grown in Nude Mice1 (1987) (1)
A phase II randomized, double-blind, placebo-controlled trial of clinical activity and safety of A6 in patients with asymptomatic CA 125 progression of epithelial ovarian, fallopian tube, or primary peritoneal cancer (2007) (1)
Validation of the predictive value of tissue inhibitor of metalloproteinases-1 for the response to first-line chemotherapy in metastatic breast cancer. (2009) (1)
1491: Measurements of Urokinase Receptor Fractions and Human Glandular Kallikrein 2 in Serum Improves Discrimination of Men with Prostate Cancer from Men with no Evidence of Malignant Disease (2005) (1)
Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRAS-mutated tumors and high plasma TIMP-1 level: Results from the NORDIC VII study. (2014) (1)
Abstract LB-476: A universal method for elimination of haemolyzed plasma samples that improves miRNA signature performance for early detection of colorectal cancer (2012) (1)
Nude mice with lacZ transduced human tumor xenografts as an in vivo model for invasion and metastasis (1991) (1)
Tumor tissue levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) and survival following adjuvant chemotherapy in pre-menopausal lymph node-positive breast cancer patients (N=525). (2009) (1)
Independent prognostic value of plasma tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer: A prospective validation study (2008) (1)
Prognostic impact of preoperative plasma tissue inhibitor of metalloproteinase 1 (pTIMP-1) in colorectal cancer (CRC) patients (Pts): A pooled analysis of 1,024 stage II/III pts. (2012) (1)
Quality control (QC) tissue array for the prospective rvaluation of translational research projects. A program of the EORTC GI and RGB Groups (2005) (1)
PPARa and PPAR ¿ are co-expressed , functional and show positive interactions in the rat urinary bladder (2010) (1)
An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort (2013) (1)
The volume regulated anion channel inhibitor NS3728 to enhance the cytotoxic effects of SN-38 in human colorectal cancer cells grown in vitro. (2016) (1)
121 MicroRNA-21 is expressed in stroma of colorectal cancers and high levels identified by image analysis predict short disease-free survival in stage II colon cancer patients (2010) (0)
Proteomic profiling of colorectal adenomas identifies a predictive risk signature for development of metachronous advanced colorectal neoplasia. (2023) (0)
1812: Enhanced Discrimination of Benign from Malignant Prostatic Disease by Novel Measurements of Cleaved Urokinase Receptor forms in Serum (2004) (0)
Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas (2018) (0)
The EORTC Laboratory Research Division. European Organisation for Research and Treatment of Cancer. (2002) (0)
[Screening methods for colorectal cancer can be improved]. (2014) (0)
Incidence of RA in people with persistently raised RF (2000) (0)
119 Soluble human urokinase receptor in plasma of nude mice during the growth of human breast cancer xenografts (1997) (0)
P5-01-14: Phosphoproteomic Analysis of TIMP-1 Overexpressing MCF-7 Human Breast Cancer Cells Reveals Increased Expression and Phosphorylation of Topoisomerase Proteins. (2011) (0)
Contents Vol. 27, 2006 (2006) (0)
Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines (2016) (0)
A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification (2016) (0)
EDITORIAL (2012) (0)
Rapid and individual-specific glycoprofiling of the cancer marker TIMP-1 (2007) (0)
Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals (2013) (0)
Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study (2013) (0)
[Breast cancer and polypeptide growth factors]. (1992) (0)
1 DNA topoisomerase I gene copy number and mRNA expression assessed as predictive biomarkers for adjuvant irinotecan in stage II/III colon cancer (2015) (0)
644 Non-small cell lung cancer (NSCLC) subtypes differs with respect to expression of components of a proteolytic enzyme system (1997) (0)
Primary tumor tissue levels of TIMP-1 and outcome following chemotherapy with docetaxel monotherapy or docetaxel in combination with gemcitabine in patients with locally advanced or metastatic breast cancer. (2010) (0)
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer (2017) (0)
WntResearch: Release of Foxy-5 GMP material for planned clinical trial (2013) (0)
Abstract B71: DEN-50R - establishment of a novel and unique cell line based drug screening platform for cancer treatment (2015) (0)
Invited commentary (2005) (0)
Abstract PS17-43: Sco-101 is a novel oral drug that reverses antiestrogen resistance in breast cancer cells (2021) (0)
Levels of Tissue Inhibitor of Metalloproteinases 1 in Plasma and Urine from Patients with Bladder Cancer (2006) (0)
The receptor for urokinase plasminogen activator is resent in both the ligand-binding and the cleaved form in ductal breast carcinoma (1994) (0)
Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical staining af formalin fixed paraffin embedded tissue (2006) (0)
Subject Index Vol. 27, 2006 (2006) (0)
The EORTC Laboratory Research Division (2002) (0)
WntResearch has now received a US Patent for its Lead Cancer Compound Foxy-5 (2014) (0)
Abstract CT264: Clinical phase II study of SCO-101 - an inhibitor of SRPK1 and ABCG2 - restoring sensitivity to FOLFIRI in metastatic FOLFIRI resistant colorectal cancer patients (2020) (0)
Su1505 The Prognostic Value of Plasma TIMP-1 in Resectable Colorectal Cancer: A Prospective Validation Study (2012) (0)
Therapy Studies in Nude Mice1 (1987) (0)
121 PAI-1 as a new target for anthnvasive and antimetastatic therapy (1997) (0)
PP 89 The prognostic value of plasma TIMP-1 in resectable colorectal cancer: a prospective validation study (2011) (0)
170 A6, a urokinase plasminogen activator (uPA)-derived peptide: a phase I trial in patients with advanced gynecologic cancer (2004) (0)
University of Southern Denmark Abcg2 protein levels and association to response to first-line irinotecan-based therapy for patients with metastatic colorectal cancer Palshof, (2020) (0)
870 Increased Soluble Cancer-Associated Biomarker Levels at Colonoscopy and Subsequent Long-Term Risk of Primary Cancer (2015) (0)
122 PAI-1 in various blood transfusion preparations (1997) (0)
TIMP-1 and the TIMP-1 interacting cell surface protein CD63 in cultured astrocytoma-derived spheroids: expression and co-expression with stem cell markers (2010) (0)
Data fusion in metabolomic cancer diagnostics (2012) (0)
Second line treatment with epirubicin to patients with metastatic colorectal cancer showing gain of the Topoisomerase IIα gene (2015) (0)
16 Immunohistochemical tissue inhibitor of metalloproteinases-1 (TIMP-1) score is a prognostic marker in glioblastoma (2008) (0)
In vitro and in vivo angiogenic assays (2002) (0)
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol (2015) (0)
P1-06-07: TIMP-1 in Combination with HER2 and TOP2A for Prediction of Benefit from Adjuvant Anthracyclines in High Risk Breast Cancer Patients. (2011) (0)
23 A comparative study of Tissue Inhibitor of Metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer (2008) (0)
The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer Review article (1999) (0)
The invariant chain CD74 protein is a cell surface binding partner of TIMP-1 in breast cancer cells. (2023) (0)
Fluids in Breast Cancer. (2004) (0)
Increased cancer-associated protein biomarker levels at bowel endoscopy and risk of extra-colonic primary cancer. (2015) (0)
Universitet TIMP-1 and responsiveness to gemcitabine in advanced breast cancer (2014) (0)
Abstract P4-07-04: Preoperative Plasma Concentration of MMP-9/TIMP-1 Complexes Is Not Associated with Disease Outcome in Primary Breast Cancer (N=483) (2010) (0)
Positron emission tomography/computed tomography for early treatment response evaluation in metastatic colon cancer. (2014) (0)
University of Southern Denmark Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 FISH analysis and plasma TIMP-1 in glioblastoma patients Aaberg-Jessen, (2016) (0)
Circulating cell-free nucleosomes as biomarkers for early detection of colorectal cancer on Early Detection of Colorectal (2018) (0)
TOP1 gene copy number in stage III colorectal cancer (CRC) samples: Association to prognosis. (2012) (0)
Evaluation of an Improved Tissue Inhibitor of Metalloproteinase 1 Dual Monoclonal Sandwich Immunoassay (2006) (0)
Abstract 1157: MicroRNA-625-3p is associated with response to first-line oxaliplatin-based treatment of metastatic colorectal cancer. (2013) (0)
Abstract P4-08-08: Cross Reactivity of Clinically Validated Anti-HER2 Antibodies (2010) (0)
MC13-0028 Prognostic significance of serum levels of intact and cleaved forms of urokinase plasminogen activator receptor (suPAR) in patients with inoperable cholangiocarcinoma (2013) (0)
University of Southern Denmark TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells A potential novel approach to the treatment of metastatic colorectal cancer (2016) (0)
BMP-2 induces EMT and breast cancer stemness through Rb and CD44 (2017) (0)
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene (2018) (0)
Analysis of Progesterone Receptor Isoforms and Proliferation in Canine Mammary Carcinomas Treated with the Antiprogestin RU534 (2014) (0)
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations (2016) (0)
Plasminogen Activator Inhibitor 1 Protects Fibrosarcoma Cells from Etoposide-Induced Apoptosis through Activation of the PI 3 K / Akt Cell Survival Pathway 1 (2014) (0)
Mendelian analysis of a metastasis‐prone substrain of BALB/c nude mice using a subcutaneously inoculated human tumour (2006) (0)
The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells (2015) (0)
Syddansk Universitet Co-expression of TIMP-1 and its cell surface binding partner CD 63 in glioblastomas (2018) (0)
99 High preoperative blood levels of urokinase plasminogen activator receptor (UPAR) and carcinoembryonic antigen (CEA) defines a group of colorectal cancer patients with poor prognosis (1997) (0)
Cell Invasion Assays (2001) (0)
104 Urokinase receptor in serum of ovarian cancer patients (1997) (0)
Abstract C168: A two stage prospective clinical trial with irofulven treatment targeting a selected subgroup of castration- and docetaxel resistant prostate cancer patients (2015) (0)
Syddansk Universitet Coexisting genomic aberrations associated with lymph node metastasis in breast cancer (2018) (0)
Abstract A182: Targeting the topoisomerase I enzyme in cancer cells with acquired resistance to SN-38 (2015) (0)
Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance (2017) (0)
Tissue inhibitor of matrix metalloprotease type-1 (TIMP-1) as a marker of cancer. (2000) (0)
Tissue inhibitor of metalloproteinases-1 (TIMP-1) and prognosis in primary breast cancer: an EORTC—RBG collaborative validation study including 2984 patients (2004) (0)
Abstract 2816: Discovery of a miRNA-based RT-qPCR signature able to detect early stage colorectal cancer in blood plasma (2011) (0)
[Can detection of cancer cells in bone marrow and peripheral blood be used in diagnosis and patient monitoring?]. (1998) (0)
The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells (2016) (0)
WntResearch to receive patent on Box-5 in Japan (2014) (0)
Genetic analysis of a metastasizing substrain of nude mice (2008) (0)
102 Urokinase plasminogen activator receptor in plasma is an independent prognostic variable in patients with colorectal cancer (1997) (0)
2031 ORAL A comparison between HER2, p53, PAI-1, angiogenesis and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer (2007) (0)
Syddansk Universitet The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells (2016) (0)
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group (2014) (0)
Syddansk Universitet TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells A potential novel approach to the treatment of metastatic colorectal cancer (2016) (0)
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene (2019) (0)
[New prognostic markers in colorectal cancer]. (1998) (0)
Early detection of colorectal cancer from patient blood plasma using microRNA-based q-rt-PCR (2010) (0)
The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer (2015) (0)
22 Total tumour tissue levels of tissue inhibitor of metalloproteinases-1 as a prognostic marker in breast cancer: an EORTC validation study of 2984 patients (2003) (0)
PP 76 Biomarker discovery using multiplexed in solution proximity extension assays: a case–control study for early detection of colorectal cancer (2011) (0)
117 Isolation and characterization of gene expression in nonmetastasizing versus metastasizing human breast cancer cells (1997) (0)
P4-01-17: TIMP-1 Over-Expression Confers Resistance of MCF-7 Breast Cancer Cells to Fulvestrant. (2011) (0)
Detection of Progesterone Receptor by qPCR Analysis from Formalin-fixed Paraffin Wax-embedded Canine Mammary Tissues (2013) (0)
Binding with Acquired Resistance to Faslodex ( ICI 182 , 780 ) B , and Cyclic AMP Response Element κ Nuclear Factor-Association of Interferon Regulatory Factor-1 , Nucleophosmin , Updated (2002) (0)
605TiP Targeting anti-cancer drug resistance in gastro-intestinal cancer: Inhibition of the SRPK1 kinase and degradation of the ABCG2 drug efflux pump (2020) (0)
Expression of Heterogeneity of Human Tumors Grown in Nude Mice1 (1987) (0)
Correlation of plasma TIMP-1 levels and disease-free survival in primary colorectal cancer independent of serum CEA levels. (2016) (0)
APO010 sensitivity in relapsed multiple myeloma patients (2016) (0)
lncRNA profile study reveals the mRNAs and lncRNAs associated with docetaxel resistance in breast cancer cells (2018) (0)
106 Association of preoperative plasma PAI-1 and CRP levels in patients with colorectal cancer (1997) (0)
HIGH LEVELS OF TIMP-1 CAN REDUCE THE EFFECT OF TOPOISOMERASE INHIBITORS ON GLIOBLASTOMA CELLS (2013) (0)
Early detection of colorectal cancer: A proteomic screening study for plasma biomarkers. (2012) (0)
Effect of TIMP-1 Overexpression on Endocrine Sensitivity of MCF-7 ER Positive Human Breast Cancer Cells In Vitro. (2009) (0)
Effect of Oophorectomy on Estrogen and Progesterone Receptor Concentrations in an Ovarian-Dependent and an Ovarian-Independent Human Breast Cancer Grown in Nude Mice (1989) (0)
101 P - Plasminogen activator inhibitor type 1 as a prognostic factor in breast cancer (1996) (0)
Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties (2013) (0)
LBA 137 Validation of a plasma based miRNA PCR test for early detection of colorectal cancer (2011) (0)
710 TIMP-1 IN PATIENTS WITH CIRRHOSIS: RELATION TO LIVER DYSFUNCTION, PORTAL HYPERTENSION, AND HAEMODYNAMIC CHANGES (2013) (0)
Plasma Tissue Inhibitor of Metallorpteinases-1 (TIMP-1) and correlation to outcome of Cetuximab-Irinotecan in heavily pre-treatedd patients with advanced colorectal cancer (2009) (0)
Plasma levels of TIMP-1 in chemo-naive patients with metastatic colorectal cancer treated with first-line FLOX with or without cetuximab: Results from the Nordic VII Study. (2013) (0)
PO-186 In vitro and clinical studies of the role of MHC class II invariant chain (CD74) in breast cancer (2018) (0)
Versatile multigene expression biomarker for predicting clinical platinum sensitivity in non-small cell lung cancer (NSCLC) and ovarian cancer (OC). (2015) (0)
Evaluation of Sample Handling in Relation to Levels of Tissue Inhibitor of Metalloproteinases-1 Measured in Blood by Immunoassay (2003) (0)
Abstract 5233: MicroRNA in biofluid as robust biomarkers for cancer (2014) (0)
Characterization of resistance to APO010, a recombinant hexameric FAS ligand, in human myeloma cell lines. (2018) (0)
Plasma TIMP-1 in patients with metastatic colorectal cancer treated with first-line oxaliplatin-based therapy with or without cetuximab: Results from the Nordic VII study. (2013) (0)
Validation of a plasma-based miRNA PCR test for early detection of colorectal cancer. (2012) (0)
TIMP-1 Status Measured by Immunohistochemistry in 268 ER Positive Postmenopausal High-Risk Breast Cancer Patients Treated with Adjuvant Tamoxifen: Association to Recurrence Free Survival. (2009) (0)
Abstract 6340: Re-sensitization of irinotecan/SN38 resistant colorectal cancer cells by SCO-101 (2020) (0)
Scandinavian Journal of Gastroenterology. Editorial. (2012) (0)
6118 The prognostic value of tissue inhibitor of metalloproteinases-1 (TIMP-1) in metastatic colorectal cancer treated with third-line cetuximab-irinotecan (2009) (0)
Early detection of colorectal neoplasia: Combination of eight cancer-associated blood-based protein biomarkers. (2016) (0)
mouse model PAI-1 and TIMP-1 gene deficiency characterized in a Gender-dependent physiological implications of combined (2007) (0)
Abstract 1912: An explorative analysis ofERCC1/ERCC4copy number alterations in a chemonaive stage III colorectal cancer patient cohort. (2013) (0)
Predictive Biomarkers and Translational Cancer Medicine (2010) (0)
TIMP-1 as a Prognostic Marker in Colorectal Cancer (2008) (0)
Urokinase-type plasminogen activator and its receptor: Involvement of stromal cells in generation of proteolytic activity during cancer invasion (1994) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Nils Age Brünner?

Nils Age Brünner is affiliated with the following schools:

Nils Age Brünner's Academic­Influence.com Rankings

Nils Age Brünner's Degrees

Similar Degrees You Can Earn

Why Is Nils Age Brünner Influential?

Nils Age Brünner's Published Works

Published Works

What Schools Are Affiliated With Nils Age Brünner?

Nils Age Brünner's AcademicInfluence.com Rankings